
Pantelis A Sarafidis

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6785665/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Mineralocorticoid receptor antagonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. Nephrology Dialysis Transplantation, 2023, 38, 10-25.	0.4	30
2	Effect of patient gender on short-term blood pressure variability in hemodialysis patients. Journal of Human Hypertension, 2023, 37, 519-523.	1.0	3
3	Opportunistic screening for hypertension: what does it say about the true epidemiology?. Journal of Human Hypertension, 2022, 36, 364-369.	1.0	3
4	Cardiopulmonary exercise testing in patients with end-stage kidney disease: principles, methodology and clinical applications of the optimal tool for exercise tolerance evaluation. Nephrology Dialysis Transplantation, 2022, 37, 2335-2350.	0.4	10
5	Prevalence and factors associated with hyperkalaemia in stable kidney transplant recipients. CKJ: Clinical Kidney Journal, 2022, 15, 43-50.	1.4	3
6	Sex differences in ambulatory blood pressure levels, control, and phenotypes of hypertension in kidney transplant recipients. Journal of Hypertension, 2022, 40, 356-363.	0.3	7
7	Cardiac geometry, function, and remodeling patterns in patients under maintenance hemodialysis and peritoneal dialysis treatment. Therapeutic Apheresis and Dialysis, 2022, 26, 601-612.	0.4	7
8	Assessment of hypertension in kidney transplantation by ambulatory blood pressure monitoring: a systematic review and meta-analysis. CKJ: Clinical Kidney Journal, 2022, 15, 31-42.	1.4	14
9	Diseases of the Aorta and Kidney Disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Cardiovascular Research, 2022, 118, 2582-2595.	1.8	6
10	Cardiopulmonary reserve examined with cardiopulmonary exercise testing in individuals with chronic kidney disease: A systematic review and meta-analysis. Annals of Physical and Rehabilitation Medicine, 2022, 65, 101588.	1.1	6
11	Lung ultrasound-guided dry-weight reduction and echocardiographic changes in clinically euvolemic hypertensive hemodialysis patients: 12-month results of a randomized controlled trial. Hellenic Journal of Cardiology, 2022, 64, 1-6.	0.4	3
12	Effects of different exercise programs on the cardiorespiratory reserve in HFpEF patients: a systematic review and meta-analysis. Hellenic Journal of Cardiology, 2022, 64, 58-66.	0.4	7
13	Mineralocorticoid receptor antagonists for cardioprotection in chronic kidney disease: a step into the future. Journal of Human Hypertension, 2022, 36, 695-704.	1.0	2
14	Lung Ultrasound as a Tool to Evaluate Fluid Accumulation in Dialysis Patients. Kidney and Blood Pressure Research, 2022, 47, 163-176.	0.9	6
15	Association of peridialytic, intradialytic, scheduled interdialytic and ambulatory BP recordings with cardiovascular events in hemodialysis patients. Journal of Nephrology, 2022, 35, 943-954.	0.9	3
16	Meta-analysis addressing the impact of cardiovascular-acting medication on peak oxygen uptake of patients with HFpEF. Heart Failure Reviews, 2022, 27, 609.	1.7	2
17	Reply. Journal of Hypertension, 2022, 40, 624-626.	0.3	0
18	Blood pressure targets in CKD 2021: the never-ending guidelines debacle. CKJ: Clinical Kidney Journal, 2022, 15, 845-851.	1.4	12

#	Article	IF	CITATIONS
19	Early morning hemodynamic changes and left ventricular hypertrophy and mortality in hemodialysis patients. Journal of Nephrology, 2022, , .	0.9	1
20	De novo Minimal Change Disease in an Adolescent after Pfizer-BioNTech COVID-19 Vaccination: A Case Report. Case Reports in Nephrology and Dialysis, 2022, 12, 44-49.	0.3	10
21	Role of Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease. Kidney and Dialysis, 2022, 2, 163-182.	0.5	5
22	Renin–angiotensin system blockers during the COVID-19 pandemic: an update for patients with hypertension and chronic kidney disease. CKJ: Clinical Kidney Journal, 2022, 15, 397-406.	1.4	10
23	Ambulatory blood pressure trajectories and blood pressure variability in kidney transplant recipients: a comparative study against haemodialysis patients. CKJ: Clinical Kidney Journal, 2022, 15, 951-960.	1.4	6
24	Intensive blood pressure control on dementia in patients with chronic kidney disease: Potential reduction in disease burden. European Journal of Internal Medicine, 2022, 101, 8-13.	1.0	3
25	MO858: Early Morning Haemodynamic Changes and Left Ventricular Hypertrophy and Mortality In Haemodialysis Patients. Nephrology Dialysis Transplantation, 2022, 37, .	0.4	0
26	MO088: Peridialytic and Intradialytic Blood Pressure Measurements are Not Valid Estimates of 44-Hour Ambulatory Blood Pressure in Patients With Intradialytic Hypertension. Nephrology Dialysis Transplantation, 2022, 37, .	0.4	0
27	MO685: Brain Oxygenation Assessed by Near-Infrared Spectroscopy During a Mental Task and a Mild Physical Stress in Hemodialysis and Peritoneal Dialysis. Nephrology Dialysis Transplantation, 2022, 37, .	0.4	0
28	MO090: Diagnostic Performance of Pre-Dialysis And Ambulatory Blood Pressure Levels in Men and Women Hemodialysis Patients. Nephrology Dialysis Transplantation, 2022, 37, .	0.4	0
29	MO087: Ambulatory Blood Pressure Trajectories and Blood Pressure Variability in Kidney Transplant Recipients: A Comparative Study Against Hemodialysis Patients. Nephrology Dialysis Transplantation, 2022, 37, .	0.4	0
30	MO198: Outcomes with Finerenone in Patients with Stage 4 Chronic Kidney Disease and Type 2 Diabetes: A Fidelity Subgroup Analysis. Nephrology Dialysis Transplantation, 2022, 37, .	0.4	0
31	MO081: Ambulatory Blood Pressure Trajectories and Blood Pressure Variability in Kidney Transplant Recipients: A Comparative Study Against Chronic Kidney Disease Patients. Nephrology Dialysis Transplantation, 2022, 37, .	0.4	0
32	MO086: Sex Differences in Ambulatory Blood Pressure Trajectories and Blood Pressure Variability in Hemodialysis Patients. Nephrology Dialysis Transplantation, 2022, 37, .	0.4	0
33	MO089: Comparison of Ambulatory Central Hemodynamics and Arterial Stiffness in Hemodialysis Patients With And Without Intradialytic Hypertension. Nephrology Dialysis Transplantation, 2022, 37, .	0.4	Ο
34	MO743: The Influence of Ambulatory Blood Pressure on the Associations of Intradialytic Hypertension with Future Cardiovascular Events and Mortality in Haemodialysis Patients. Nephrology Dialysis Transplantation, 2022, 37, .	0.4	0
35	FC085: Cerebral Oxygenation During Exercise Across Different Stages of Chronic Kidney Disease. Nephrology Dialysis Transplantation, 2022, 37, .	0.4	0
36	Sex differences in ambulatory blood pressure levels, control and phenotypes of hypertension in hemodialysis patients. Journal of Hypertension, 2022, 40, 1735-1743.	0.3	1

#	Article	IF	CITATIONS
37	Volume overload in hemodialysis: diagnosis, cardiovascular consequences, and management. Nephrology Dialysis Transplantation, 2021, 36, 2182-2193.	0.4	45
38	The European/International Fibromuscular Dysplasia Registry and Initiative (FEIRI)—clinical phenotypes and their predictors based on a cohort of 1000 patients. Cardiovascular Research, 2021, 117, 950-959.	1.8	33
39	Benefits and risks of frequent or longer haemodialysis: weighing the evidence. Nephrology Dialysis Transplantation, 2021, 36, 1168-1176.	0.4	8
40	SGLT-2 inhibitors and nephroprotection: current evidence and future perspectives. Journal of Human Hypertension, 2021, 35, 12-25.	1.0	30
41	Microcirculatory function deteriorates with advancing stages of chronic kidney disease independently of arterial stiffness and atherosclerosis. Hypertension Research, 2021, 44, 179-187.	1.5	17
42	Associations of serum sclerostin and Dickkopf-related protein-1 proteins with future cardiovascular events and mortality in haemodialysis patients: a prospective cohort study. CKJ: Clinical Kidney Journal, 2021, 14, 1165-1172.	1.4	5
43	The Effects of Nebivolol and Irbesartan on Ambulatory Aortic Blood Pressure and Arterial Stiffness in Hemodialysis Patients with Intradialytic Hypertension. Blood Purification, 2021, 50, 73-83.	0.9	4
44	The presence of diabetes mellitus further impairs structural and functional capillary density in patients with chronic kidney disease. Microcirculation, 2021, 28, e12665.	1.0	12
45	Dapagliflozin Does Not Affect Short-Term Blood Pressure Variability in Patients With Type 2 Diabetes Mellitus. American Journal of Hypertension, 2021, 34, 404-413.	1.0	7
46	Intravenous iron therapy and the cardiovascular system: risks and benefits. CKJ: Clinical Kidney Journal, 2021, 14, 1067-1076.	1.4	12
47	Proton Pump Inhibitors, Histamine-2 Receptor Antagonists, and the Risk of Kidney Stones: Negligible or Not?. Clinical Gastroenterology and Hepatology, 2021, 19, 624-625.	2.4	1
48	Haemodialysis and peritoneal dialysis patients have severely impaired post-occlusive skin forearm vasodilatory response assessed with laser speckle contrast imaging. CKJ: Clinical Kidney Journal, 2021, 14, 1419-1427.	1.4	14
49	Effects of intradialytic exercise on physical performance and cardiopulmonary fitness: promises that need to be confirmed. International Urology and Nephrology, 2021, 53, 1953-1954.	0.6	0
50	The effect of admission and pre-admission serum creatinine as baseline to assess incidence and outcomes of acute kidney injury in acute medical admissions. Nephrology Dialysis Transplantation, 2021, , .	0.4	4
51	Sodiumglucose co-transporter-2 inhibitors for patients with diabetic and nondiabetic chronic kidney disease: a new era has already begun. Journal of Hypertension, 2021, 39, 1090-1097.	0.3	22
52	Assessment of Exercise Intolerance in Patients with Pre-Dialysis CKD with Cardiopulmonary Function Testing: Translation to Everyday Practice. American Journal of Nephrology, 2021, 52, 264-278.	1.4	8
53	Renin-angiotensin system blockade in patients with chronic kidney disease: benefits, problems in everyday clinical use, and open questions for advanced renal dysfunction. Journal of Human Hypertension, 2021, 35, 499-509.	1.0	14
54	Blood pressure monitoring in kidney transplantation: a systematic review on hypertension and target organ damage. Nephrology Dialysis Transplantation, 2021, 36, 1326-1346.	0.4	18

#	Article	IF	CITATIONS
55	Renal tubular transport protein regulation in primary aldosteronism: can large-scale proteomic analysis offer a new insight?. Journal of Human Hypertension, 2021, 35, 825-827.	1.0	2
56	Nailfold Capillaroscopy in Systemic Sclerosis Patients with and without Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis. Journal of Clinical Medicine, 2021, 10, 1528.	1.0	17
57	Acute kidney injury is more common in men than women after accounting for socioeconomic status, ethnicity, alcohol intake and smoking history. Biology of Sex Differences, 2021, 12, 30.	1.8	24
58	Vascular endothelial injury assessed with functional techniques in systemic sclerosis patients with pulmonary arterial hypertension versus systemic sclerosis patients without pulmonary arterial hypertension: a systematic review and meta-analysis. Rheumatology International, 2021, 41, 1045-1053.	1.5	10
59	Εndothelial and microvascular function in CKD: Evaluation methods and associations with outcomes. European Journal of Clinical Investigation, 2021, 51, e13557.	1.7	6
60	Sex differences in the progression of kidney injury and risk of death in CKD patients: is different ambulatory blood pressure control the underlying cause?. Nephrology Dialysis Transplantation, 2021, 36, 1965-1967.	0.4	1
61	Accuracy of Peridialytic, Intradialytic, and Scheduled Interdialytic Recordings in Detecting Elevated Ambulatory Blood Pressure in Hemodialysis Patients. American Journal of Kidney Diseases, 2021, 78, 630-639.e1.	2.1	7
62	MO611CARDIOPULMONARY RESERVE EXAMINED WITH CARDIOPULMONARY EXERCISE TESTING IN INDIVIDUALS WITH AND WITHOUT CHRONIC KIDNEY DISEASE; A SYSTEMATIC REVIEW AND META-ANALYSIS. Nephrology Dialysis Transplantation, 2021, 36, .	0.4	1
63	Cardiovascular Protection With Sodium-Glucose Cotransporter-2 Inhibitors and Mineralocorticoid Receptor Antagonists in Chronic Kidney Disease. Hypertension, 2021, 77, 1442-1455.	1.3	22
64	Hypertension in kidney transplantation: a consensus statement of the â€~hypertension and the kidney' working group of the European Society of Hypertension. Journal of Hypertension, 2021, 39, 1513-1521.	0.3	16
65	MO729LUNG ULTRASOUND GUIDED DRY-WEIGHT REDUCTION DECREASES CARDIAC CHAMBERS DIMENSIONS AND IMPROVES VENTRICULAR DIASTOLIC FUNCTION IN HEMODIALYSIS PATIENTS: LONG-TERM ANALYSIS OF A LUST SUB-STUDY. Nephrology Dialysis Transplantation, 2021, 36, .	0.4	0
66	MO102LUNG ULTRASOUND-GUIDED DRY-WEIGHT REDUCTION DECREASES AMBULATORY BLOOD PRESSURE LEVELS IN HYPERTENSIVE HEMODIALYSIS PATIENTS: LONG-TERM ANALYSIS OF A LUST SUB-STUDY*. Nephrology Dialysis Transplantation, 2021, 36, .	0.4	0
67	MO953PREVALENCE AND FACTORS ASSOCIATED WITH HYPERKALAEMIA IN STABLE KIDNEY TRANSPLANT RECIPIENTS WITH PRESERVED RENAL FUNCTION. Nephrology Dialysis Transplantation, 2021, 36, .	0.4	1
68	MO108ACCURACY OF PERIDIALYTIC, INTRADIALYTIC AND SCHEDULED INTERDIALYTIC RECORDINGS FOR DIAGNOSING HIGH AMBULATORY BLOOD PRESSURE IN HEMODIALYSIS. Nephrology Dialysis Transplantation, 2021, 36, .	0.4	0
69	MO103PREDICTION OF CARDIOVASCULAR OUTCOMES WITH PERIDIALYTIC, INTRADIALYTIC, SCHEDULED INTERDIALYTIC AND AMBULATORY BP RECORDINGS IN HEMODIALYSIS PATIENTS. Nephrology Dialysis Transplantation, 2021, 36, .	0.4	0
70	FC 104CARDIAC GEOMETRY, FUNCTION, AND REMODELING PATTENRS AND LUNG WATER CONTENT IN PATIENTS UNDER MAINTENANCE HEMODIALYSIS AND PERITONEAL DIALYSIS TREATMENT. Nephrology Dialysis Transplantation, 2021, 36, .	0.4	0
71	MO642DAPAGLIFLOZIN HAS NO IMPACT ON SHORT-TERM BLOOD PRESSURE VARIABILITY IN PATIENTS WITH TYPE-2 DIABETES MELLITUS. Nephrology Dialysis Transplantation, 2021, 36, .	0.4	0
72	Role of hypertension in kidney transplant recipients. Journal of Human Hypertension, 2021, 35, 958-969.	1.0	10

#	Article	IF	CITATIONS
73	Opportunistic screening for hypertension in the general population in Greece: International Society of Hypertension May Measurement Month 2019. European Heart Journal Supplements, 2021, 23, B66-B69.	0.0	2
74	FC 090EFFECTS OF FINERENONE ON CARDIORENAL OUTCOMES IN BLOOD PRESSURE SUBGROUPS IN PATIENTS WITH CKD AND T2D. Nephrology Dialysis Transplantation, 2021, 36, .	0.4	2
75	Dapagliflozin does not affect blood pressure variability in prediabetic prehypertensive subjects. Blood Pressure Monitoring, 2021, 26, 242-243.	0.4	1
76	Central and peripheral arterial diseases in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International, 2021, 100, 35-48.	2.6	26
77	Hyperkalemia in Chronic Kidney Disease in the New Era of Kidney Protection Therapies. Drugs, 2021, 81, 1467-1489.	4.9	22
78	Cardiorespiratory fitness assessed by cardiopulmonary exercise testing between different stages of preâ€dialysis chronic kidney disease: A systematic review and metaâ€analysis. Nephrology, 2021, 26, 972-980.	0.7	7
79	Ambulatory blood pressure changes with lung ultrasound-guided dry-weight reduction in hypertensive hemodialysis patients: 12-month results of a randomized controlled trial. Journal of Hypertension, 2021, 39, 1444-1452.	0.3	4
80	<scp>Sodiumâ€glucose</scp> cotransporter 2 inhibitors for diabetes mellitus control after kidney transplantation: Review of the current evidence. Nephrology, 2021, 26, 1007-1017.	0.7	10
81	Cardiorespiratory fitness in kidney transplant recipients compared to patients with kidney failure: a systematic review and metaâ€analysis. Transplant International, 2021, 34, 1801-1811.	0.8	2
82	A randomized multicenter trial on a lung ultrasound–guided treatment strategy in patients on chronic hemodialysis with high cardiovascular risk. Kidney International, 2021, 100, 1325-1333.	2.6	45
83	Diagnostic Performance of Office versus Ambulatory Blood Pressure in Kidney Transplant Recipients. American Journal of Nephrology, 2021, 52, 548-558.	1.4	13
84	Kidney transplantation improving cardiopulmonary exercise responses: still some way to go before conclusive evidence. CKJ: Clinical Kidney Journal, 2021, 14, 1483-1484.	1.4	2
85	Simplifying volume assessment with lung ultrasound in paediatric haemodialysis patients. CKJ: Clinical Kidney Journal, 2021, 14, 1708-1709.	1.4	1
86	Can the assessment of ultrasound lung water in haemodialysis patients be simplified?. Nephrology Dialysis Transplantation, 2021, 36, 2321-2326.	0.4	15
87	Dapagliflozin decreases ambulatory central blood pressure and pulse wave velocity in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled clinical trial. Journal of Hypertension, 2021, 39, 749-758.	0.3	38
88	Nocturnal dipping profile in chronic kidney disease: Searching for underlying mechanisms in order to prevent adverse events. Physiological Reports, 2021, 8, e14665.	0.7	0
89	Comparative effectiveness of different antihypertensive agents in kidney transplantation: a systematic review and meta-analysis. Nephrology Dialysis Transplantation, 2020, 35, 878-887.	0.4	32
90	Lung Ultrasound–Guided Dry Weight Assessment and Echocardiographic Measures in Hypertensive Hemodialysis Patients: A Randomized Controlled Study. American Journal of Kidney Diseases, 2020, 75, 11-20.	2.1	42

#	Article	IF	CITATIONS
91	Inflammation is an amplifier of lung congestion by high lv filling pressure in hemodialysis patients: a longitudinal study. Journal of Nephrology, 2020, 33, 583-590.	0.9	4
92	The risk for urinary tract infections with sodium-glucose cotransporter 2 inhibitors: no longer a cause of concern?. CKJ: Clinical Kidney Journal, 2020, 13, 24-26.	1.4	18
93	Hyponatremia accompanying volatile hypertension caused by baroreflex failure after neck surgery: case report and literature review. Journal of Hypertension, 2020, 38, 1617-1624.	0.3	3
94	SGLT2 inhibitors for non-diabetic kidney disease: drugs to treat CKD that also improve glycaemia. CKJ: Clinical Kidney Journal, 2020, 13, 728-733.	1.4	68
95	Severe euglycemic diabetic ketoacidosis of multifactorial etiology in a type 2 diabetic patient treated with empagliflozin: case report and literature review. BMC Nephrology, 2020, 21, 276.	0.8	16
96	Diastolic Blood Pressure Does Not Influence Cardiovascular Outcomes in Type 2 Diabetes; or Does It?. Diabetes Care, 2020, 43, 1684-1686.	4.3	2
97	Assessment of Hydration Status in Peritoneal Dialysis Patients: Validity, Prognostic Value, Strengths, and Limitations of Available Techniques. American Journal of Nephrology, 2020, 51, 589-612.	1.4	23
98	Comparison of ambulatory central hemodynamics and arterial stiffness in patients with diabetic and nonâ€diabetic CKD. Journal of Clinical Hypertension, 2020, 22, 2239-2249.	1.0	4
99	Heart Failure and Atrial Fibrillation Modify the Associations of Nocturnal Blood Pressure Dipping Pattern With Mortality in Hemodialysis Patients. Hypertension, 2020, 76, 1231-1239.	1.3	3
100	Treatment-resistant hypertension in the hemodialysis population: a 44-h ambulatory blood pressure monitoring-based study. Journal of Hypertension, 2020, 38, 1849-1856.	0.3	15
101	Assessment of Endothelial and Microvascular Function in CKD: Older and Newer Techniques, Associated Risk Factors, and Relations with Outcomes. American Journal of Nephrology, 2020, 51, 931-949.	1.4	16
102	P1026THE EFFECT OF DAPAGLIFLOZIN ON 24-HOUR BLOOD PRESSURE IN PATIENTS WITH TYPE-2 DIABETES MELLITUS: A DOUBLE-BLIND RANDOMIZED CLINICAL TRIAL. Nephrology Dialysis Transplantation, 2020, 35, .	0.4	0
103	Ambulatory blood pressure profile and blood pressure variability in peritoneal dialysis compared with hemodialysis and chronic kidney disease patients. Hypertension Research, 2020, 43, 903-913.	1.5	21
104	Are endourological procedures for nephrolithiasis treatment associated with renal injury? A review of potential mechanisms and novel diagnostic indexes. CKJ: Clinical Kidney Journal, 2020, 13, 531-541.	1.4	7
105	Euglycaemic diabetic ketoacidosis as a complication of SGLT-2 inhibitors: epidemiology, pathophysiology, and treatment. Expert Opinion on Drug Safety, 2020, 19, 673-682.	1.0	8
106	SO036THE EFFECT OF DAPAGLIFLOZIN ON AMBULATORY AORTIC BLOOD PRESSURE AND ARTERIAL STIFFNESS PARAMETERS IN PATIENTS WITH TYPE-2 DIABETES MELLITUS: A DOUBLE-BLIND RANDOMIZED CLINICAL TRIAL. Nephrology Dialysis Transplantation, 2020, 35, .	0.4	1
107	Longer Dialysis Sessions Improve Cardiac Systolic Function by Reducing Myocardial Stunning. Journal of Cardiac Failure, 2020, 26, 1026-1027.	0.7	2
108	Blood pressure targets in patients with chronic kidney disease: MDRD and AASK now confirming SPRINT. CKJ: Clinical Kidney Journal, 2020, 13, 287-290.	1.4	5

#	Article	IF	CITATIONS
109	Blood pressure and volume management in dialysis: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International, 2020, 97, 861-876.	2.6	126
110	Exploring Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors for Organ Protection in COVID-19. Journal of Clinical Medicine, 2020, 9, 2030.	1.0	28
111	SGLT-2 Inhibitors to Treat Hyponatremia Associated with SIADH: A Novel Indication?. American Journal of Nephrology, 2020, 51, 553-555.	1.4	12
112	Management of atrial fibrillation in patients with chronic kidney disease in clinical practice: a joint European Heart Rhythm Association (EHRA) and European Renal Association/European Dialysis and Transplantation Association (ERA/EDTA) physician-based survey. Europace, 2020, 22, 496-505.	0.7	29
113	TNF-α pathway and T-cell immunity are activated early during the development of diabetic nephropathy in Type II Diabetes Mellitus. Clinical Immunology, 2020, 215, 108423.	1.4	30
114	Ambulatory Blood Pressure Trajectories and Blood Pressure Variability in Diabetic and Non-Diabetic Chronic Kidney Disease. American Journal of Nephrology, 2020, 51, 411-420.	1.4	2
115	Fractioned urine collections to assess urine supersaturation in urolithiasis; a pathway worth exploring. Urolithiasis, 2020, 48, 465-466.	1.2	0
116	Excess volume removal following lung ultrasound evaluation decreases central blood pressure and pulse wave velocity in hemodialysis patients: a LUST sub-study. Journal of Nephrology, 2020, 33, 1289-1300.	0.9	7
117	Pharmacotherapy of hypertension in patients with pre-dialysis chronic kidney disease. Expert Opinion on Pharmacotherapy, 2020, 21, 1201-1217.	0.9	2
118	A comparative study of ambulatory central hemodynamics and arterial stiffness parameters in peritoneal dialysis and hemodialysis patients. Journal of Hypertension, 2020, 38, 2393-2403.	0.3	4
119	Chronic Therapy with Sucroferric Oxyhydroxide Does Not Affect Iron and Anemia Markers in Dialysis Patients. Blood Purification, 2020, 49, 440-447.	0.9	6
120	The Beneficial Hemodynamic Actions of SGLT-2 Inhibitors beyond the Management of Hyperglycemia. Current Medicinal Chemistry, 2020, 27, 6682-6702.	1.2	16
121	In Reply to â€~Lung Ultrasound in Hemodialysis Patients: Is it Practical to Scan 28 Zones?'. American Journal of Kidney Diseases, 2020, 75, 816.	2.1	Ο
122	Serum Copeptin, NLPR3, and suPAR Levels among Patients with Autosomal-Dominant Polycystic Kidney Disease with and without Impaired Renal Function. CardioRenal Medicine, 2020, 10, 440-451.	0.7	4
123	Hypertension Management in Patients With Autosomal Dominant Polycystic Kidney Disease: Time for a Paradigm Shift?. American Journal of Kidney Diseases, 2020, 76, 743.	2.1	1
124	Prevalence and control of hypertension by 48-h ambulatory blood pressure monitoring in haemodialysis patients: a study by the European Cardiovascular and Renal Medicine (EURECA-m) working group of the ERA-EDTA. Nephrology Dialysis Transplantation, 2019, 34, 1542-1548.	0.4	21
125	FP685THE PROGNOSTIC SIGNIFICANCE OF THE BLOOD PRESSURE-PULSE WAVE VELOCITY ASSOCIATION FOR CARDIOVASCULAR OUTCOMES AND MORTALITY IN HEMODIALYSIS PATIENTS. Nephrology Dialysis Transplantation, 2019, 34, .	0.4	Ο
126	Increased Sclerostin, but Not Dickkopf-1 Protein, Is Associated with Elevated Pulse Wave Velocity in Hemodialysis Subjects. Kidney and Blood Pressure Research, 2019, 44, 679-689.	0.9	11

#	Article	IF	CITATIONS
127	SP054SHORT-TERM BLOOD PRESSURE VARIABILITY IS REDUCED AFTER NEBIVOLOL COMPARED TO IRBESARTAN TREATMENT IN PATIENTS WITH INTRADIALYTIC HYPERTENSION. Nephrology Dialysis Transplantation, 2019, 34, .	0.4	0
128	Is blood pressure measured correctly in dialysis centres? Physicians' and patients' views. Nephrology Dialysis Transplantation, 2019, 34, 1612-1615.	0.4	6
129	FO001Low plasma Klotho is associated with cardiovascular events in hemodialysis, independently of major risk factors, FGF-23, arterial stiffness and intima-media-thickness. Nephrology Dialysis Transplantation, 2019, 34, .	0.4	1
130	FO041THE EFFECT OF DRY-WEIGHT REDUCTION GUIDED BY LUNG ULTRASOUND ON AMBULATORY BLOOD PRESSURE IN HEMODIALYSIS PATIENTS: A LUST SUB-STUDY. Nephrology Dialysis Transplantation, 2019, 34, .	0.4	0
131	FP817ASSESSMENT OF HYDRATION STATUS CHANGES BY BIO-IMPEDANCE SPECTROSCOPY IN CHILDREN ON PERITONEAL DIALYSIS. Nephrology Dialysis Transplantation, 2019, 34, .	0.4	0
132	The effect of SGLT-2 inhibitors on blood pressure: a pleiotropic action favoring cardio- and nephroprotection. Future Medicinal Chemistry, 2019, 11, 1285-1303.	1.1	15
133	SaO019LUNG ULTRASOUND GUIDED DRY-WEIGHT PROBING REDUCES CARDIAC CHAMBERS DIMENSIONS AND LEFT VENTRICULAR FILLING PRESSURES IN HEMODIALYSIS PATIENTS WITH HYPERTENSION. Nephrology Dialysis Transplantation, 2019, 34, .	0.4	0
134	SaOO48THE EFFECT OF DRY-WEIGHT REDUCTION GUIDED BY LUNG ULTRASOUND ON AMBULATORY AORTIC BLOOD PRESSURE AND ARTERIAL STIFFNESS PARAMETERS IN HEMODIALYSIS PATIENTS: A LUST SUB-STUDY. Nephrology Dialysis Transplantation, 2019, 34, .	0.4	0
135	SP544A COMPARATIVE STUDY OF SHORT-TERM BP VARIABILITY IN HEMODIALYSIS PATIENTS WITH AND WITHOUT INTRADIALYTIC HYPERTENSION. Nephrology Dialysis Transplantation, 2019, 34, .	0.4	0
136	SP622CHRONIC THERAPY WITH SUCROFERRIC OXYHYDROXIDE DOES NOT AFFECT IRON AND ANEMIA MARKERS IN DIALYSIS PATIENTS. Nephrology Dialysis Transplantation, 2019, 34, .	0.4	0
137	FP172EFFECTS OF MINERALOCORTICOID RECEPTOR ANTAGONISTS IN PROTEINURIC KIDNEY DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS. Nephrology Dialysis Transplantation, 2019, 34, .	0.4	0
138	FP516THE RENOPROTECTIVE EFFECTS OF SODIUM-GLUCOSE CO-TRANSPORTER 2 INHIBITORS IN DIABETES MELLITUS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS. Nephrology Dialysis Transplantation, 2019, 34, .	0.4	0
139	FP619BLOOD PRESSURE VARIABILITY INDEXES DURING THE LONG INTERDIALYTIC INTERVAL IN HEMODIALYSIS PATIENTS. Nephrology Dialysis Transplantation, 2019, 34, .	0.4	0
140	FP680THE PREDICTIVE VALUE OF NOCTURNAL BLOOD PRESSURE DIPPING PATTERNS IS CRITICALLY AFFECTED BY HEART FAILURE AND ATRIAL FIBRILLATION IN PATIENTS UNDERGOING HEMODIALYSIS. Nephrology Dialysis Transplantation, 2019, 34, .	0.4	0
141	FP690APPARENT TREATMENT-RESISTANT HYPERTENSION IN THE HEMODIALYSIS POPULATION: AN AMBULATORY BP MONITORING (ABPM) BASED STUDY. Nephrology Dialysis Transplantation, 2019, 34, .	0.4	0
142	FP760COMPARATIVE EFFECTIVENESS OF DIFFERENT ANTIHYPERTENSIVE AGENTS IN KIDNEY TRANSPLANTATION: A SYSTEMATIC REVIEW AND META-ANALYSIS. Nephrology Dialysis Transplantation, 2019, 34, .	0.4	0
143	Arterial Stiffness in Patients With Renal Transplantation; Associations With Co-morbid Conditions, Evolution, and Prognostic Importance for Cardiovascular and Renal Outcomes. Frontiers in Cardiovascular Medicine, 2019, 6, 67.	1.1	18
144	Lung Ultrasound-Guided Dry-Weight Reduction in Hemodialysis Patients Does Not Affect Short-Term Blood Pressure Variability. American Journal of Hypertension, 2019, 32, 786-795.	1.0	12

#	Article	IF	CITATIONS
145	Soluble Klotho is associated with mortality and cardiovascular events in hemodialysis. BMC Nephrology, 2019, 20, 217.	0.8	61
146	The effect of dry-weight reduction guided by lung ultrasound on ambulatory blood pressure in hemodialysis patients: a randomized controlled trial. Kidney International, 2019, 95, 1505-1513.	2.6	65
147	Comparison of 24-hour and Office Pulse Wave Velocity for Prediction of Mortality in Hemodialysis Patients. American Journal of Nephrology, 2019, 49, 317-327.	1.4	24
148	Beta-thalassemia: renal complications and mechanisms: a narrative review. Hematology, 2019, 24, 426-438.	0.7	31
149	SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA. Nephrology Dialysis Transplantation, 2019, 34, 208-230.	0.4	147
150	Sodium–Glucose Cotransporter-2 Inhibitors and Urinary Tract Infections. Annals of Internal Medicine, 2019, 171, 943.	2.0	0
151	Hypoxia and Endothelial Dysfunction in Autosomal-Dominant Polycystic Kidney Disease. Seminars in Nephrology, 2019, 39, 599-612.	0.6	15
152	Effects of mineralocorticoid receptor antagonists in proteinuric kidney disease. Journal of Hypertension, 2019, 37, 2307-2324.	0.3	66
153	The effect of SGLT-2 inhibitors on albuminuria and proteinuria in diabetes mellitus. Journal of Hypertension, 2019, 37, 1334-1343.	0.3	43
154	Weak within-individual association of blood pressure and pulse wave velocity in hemodialysis is related to adverse outcomes. Journal of Hypertension, 2019, 37, 2200-2208.	0.3	10
155	The association of interdialytic blood pressure variability with cardiovascular events and all-cause mortality in haemodialysis patients. Nephrology Dialysis Transplantation, 2019, 34, 515-523.	0.4	40
156	The effects of nebivolol and irbesartan on postdialysis and ambulatory blood pressure in patients with intradialytic hypertension. Journal of Hypertension, 2019, 37, 432-442.	0.3	10
157	Nebivolol reduces short-term blood pressure variability more potently than irbesartan in patients with intradialytic hypertension. Hypertension Research, 2019, 42, 1001-1010.	1.5	13
158	Mineralocorticoid Receptor Antagonists for Nephroprotection: Current Evidence and Future Perspectives. Current Pharmaceutical Design, 2019, 24, 5528-5536.	0.9	20
159	Renal injury progression in autosomal dominant polycystic kidney disease: a look beyond the cysts. Nephrology Dialysis Transplantation, 2018, 33, 1887-1895.	0.4	17
160	Blood pressure variability increases with advancing chronic kidney disease stage. Journal of Hypertension, 2018, 36, 1076-1085.	0.3	63
161	The Ebb and Flow of Echocardiographic Cardiac Function Parameters in Relationship to Hemodialysis Treatment in Patients with ESRD. Journal of the American Society of Nephrology: JASN, 2018, 29, 1372-1381.	3.0	29
162	Levels of Endocan, Angiopoietin-2, and Hypoxia-Inducible Factor-1a in Patients with Autosomal Dominant Polycystic Kidney Disease and Different Levels of Renal Function. American Journal of Nephrology, 2018, 47, 231-238.	1.4	17

#	Article	IF	CITATIONS
163	Should renal color Doppler ultrasonography be a routine test in newly diagnosed hypertensive patient?. Journal of Hypertension, 2018, 36, 16-22.	0.3	5
164	SP082THE EFFECTS OF NEBIVOLOL AND IRBESARTAN ON CENTRAL BLOOD PRESSURE AND ARTERIAL STIFNESS PARAMETERS IN HEMODIALYSIS PATIENTS WITH INTRADIALYTIC HYPERTENSION. Nephrology Dialysis Transplantation, 2018, 33, i373-i373.	0.4	0
165	A Comparative Study of Short-Term Blood Pressure Variability in Hemodialysis Patients with and without Intradialytic Hypertension. American Journal of Nephrology, 2018, 48, 295-305.	1.4	21
166	Lipid management in patients with chronic kidney disease. Nature Reviews Nephrology, 2018, 14, 727-749.	4.1	153
167	FP639AMBULATORY 24H BLOOD PRESSURE AND MORTALITY IN HEMODIALYSIS PATIENTS: A U-SHAPED ASSOCIATION DEPENDING ON THE CARDIAC FUNCTION. Nephrology Dialysis Transplantation, 2018, 33, i258-i259.	0.4	1
168	Antihypertensive therapy in acute ischemic stroke: where do we stand?. Journal of Human Hypertension, 2018, 32, 799-807.	1.0	7
169	FP055LEVELS OF SERUM SFAS, MYOSTATIN AND URINE TGF.β1 ARE HIGH IN PATIENTS WITH AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE WITH PRESERVED AND LOW RENAL FUNCTION. Nephrology Dialysis Transplantation, 2018, 33, i66-i66.	0.4	0
170	FP058LEVELS OF ENDOCAN, ANGIOPOIETIN-2 AND HIF-1A IN PATIENTS WITH AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE AND DIFFERENT LEVELS OF RENAL FUNCTION. Nephrology Dialysis Transplantation, 2018, 33, i67-i67.	0.4	0
171	SP086NEBIVOLOL AND IRBESARTAN REDUCE POST-HEMODIALYSIS AND AMBULATORY BP IN PATIENTS WITH INTRADIALYTIC HYPERTENSION: A RANDOMIZED CROSS-OVER STUDY. Nephrology Dialysis Transplantation, 2018, 33, i374-i374.	0.4	0
172	Serum Fas Ligand, Serum Myostatin and Urine TGF-β1 Are Elevated in Autosomal Dominant Polycystic Kidney Disease Patients with Impaired and Preserved Renal Function. Kidney and Blood Pressure Research, 2018, 43, 744-754.	0.9	11
173	The optimal blood pressure target in diabetes mellitus: a quest coming to an end?. Journal of Human Hypertension, 2018, 32, 641-650.	1.0	12
174	Association of Ambulatory Blood Pressure with All-Cause and Cardiovascular Mortality in Hemodialysis Patients: Effects of Heart Failure and Atrial Fibrillation. Journal of the American Society of Nephrology: JASN, 2018, 29, 2409-2417.	3.0	24
175	Serum Creatinine and Chronic Kidney Disease-Epidemiology Estimated Glomerular Filtration Rate: Independent Predictors of Renal Replacement Therapy following Cardiac Surgery. American Journal of Nephrology, 2018, 48, 108-117.	1.4	12
176	Hypertension in Dialysis Patients: Clinical Epidemiology, Pathogenesis, Diagnosis, and Treatment. Updates in Hypertension and Cardiovascular Protection, 2018, , 383-417.	0.1	0
177	Blood pressure reduction in diabetes: lessons from ACCORD, SPRINT and EMPA-REG OUTCOME. Nature Reviews Endocrinology, 2017, 13, 365-374.	4.3	29
178	Renal Artery Stenosis in Patients with Resistant Hypertension: Stent It or Not?. Current Hypertension Reports, 2017, 19, 5.	1.5	21
179	Hypertension in dialysis patients: a consensus document by the European Renal and Cardiovascular Medicine (EURECA-m) working group of the European Renal Association–European Dialysis and Transplant Association (ERA-EDTA) and the Hypertension and the Kidney working group of the European Society of Hypertension (ESH)*, Nephrology Dialysis Transplantation, 2017, 32, 620-640.	0.4	133
180	The systemic nature of CKD. Nature Reviews Nephrology, 2017, 13, 344-358.	4.1	265

180 The systemic nature of CKD. Nature Reviews Nephrology, 2017, 13, 344-358.

#	Article	IF	CITATIONS
181	A review of chemical therapies for treating diabetic hypertension. Expert Opinion on Pharmacotherapy, 2017, 18, 909-923.	0.9	8
182	Ambulatory Pulse Wave Velocity Is a Stronger Predictor of Cardiovascular Events and All-Cause Mortality Than Office and Ambulatory Blood Pressure in Hemodialysis Patients. Hypertension, 2017, 70, 148-157.	1.3	96
183	Has the SPRINT trial introduced a new blood-pressure goal in hypertension?. Nature Reviews Cardiology, 2017, 14, 560-565.	6.1	19
184	Hypertension in dialysis patients. Journal of Hypertension, 2017, 35, 657-676.	0.3	56
185	Diagnosis of tuberous sclerosis complex in a patient referred for uncontrolled hypertension and renal dysfunction. Journal of Hypertension, 2017, 35, 2109-2114.	0.3	3
186	Endovascular aneurysm repair (EVAR)– and transcatheter aortic valve replacement (TAVR)–associated acute kidney injury. Kidney International, 2017, 91, 1312-1323.	2.6	37
187	Online Hemodiafiltration Improves Outcomes in Incident Patients with End-Stage Renal Disease: Another Brick in the Wall?. American Journal of Nephrology, 2017, 46, 285-287.	1.4	0
188	Blood pressure variability is increasing from the first to the second day of the interdialytic interval in hemodialysis patients. Journal of Hypertension, 2017, 35, 2517-2526.	0.3	28
189	Optimizing hypertension management in renal transplantation: a call to action. Nephrology Dialysis Transplantation, 2017, 32, 1959-1962.	0.4	14
190	The Clinical Problems of Hypertension Treatment in Hemodialysis Patients. Current Vascular Pharmacology, 2017, 16, 54-60.	0.8	16
191	A Case of Pulmonary-Renal Syndrome Leading to the Diagnosis of Legionnaires' Disease. Case Reports in Nephrology, 2016, 2016, 1-5.	0.2	3
192	MP217DIABETES MELLITUS DOES NOT INCREASE THE INCIDENCE OF ACUTE KIDNEY INJURY AFTER CARDIAC SURGERY IN PATIENTS WITH CHRONIC KIDNEY DISEASE; A NESTED CASE-CONTROL STUDY. Nephrology Dialysis Transplantation, 2016, 31, i412-i412.	0.4	0
193	Renal Function is the Main Predictor of Acute Kidney Injury after Endovascular Abdominal Aortic Aneurysm Repair. Annals of Vascular Surgery, 2016, 31, 52-59.	0.4	38
194	Diabetes mellitus does not affect the incidence of acute kidney injury after cardiac surgery; a nested case–control study. Journal of Nephrology, 2016, 29, 835-845.	0.9	6
195	Global cardiovascular protection in chronic kidney disease. Nature Reviews Cardiology, 2016, 13, 603-608.	6.1	36
196	Hypertension in Chronic Kidney Disease Part 1. Hypertension, 2016, 67, 1093-1101.	1.3	63
197	Hypertension in Chronic Kidney Disease Part 2. Hypertension, 2016, 67, 1102-1110.	1.3	86
198	Efficacy of a remote web-based lung ultrasound training for nephrologists and cardiologists: a LUST trial sub-project. Nephrology Dialysis Transplantation, 2016, 31, 1982-1988.	0.4	60

#	Article	IF	CITATIONS
199	The Agreement between Auscultation and Lung Ultrasound in Hemodialysis Patients: The LUST Study. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 2005-2011.	2.2	124
200	Mineralocorticoid Receptor Antagonism for Cardiovascular Protection in End‣tage Renal Disease: New Data But the Controversy Continues. Journal of Clinical Hypertension, 2016, 18, 197-199.	1.0	4
201	Echocardiographic Parameters During Long and Short Interdialytic Intervals in Hemodialysis Patients. American Journal of Kidney Diseases, 2016, 68, 772-781.	2.1	22
202	Association Between High and Very High Albuminuria and Nighttime Blood Pressure: Influence of Diabetes and Chronic Kidney Disease. Diabetes Care, 2016, 39, 1729-1737.	4.3	26
203	Haemodialysis acutely deteriorates left and right diastolic function and myocardial performance: an effect related to high ultrafiltration volumes?. Nephrology Dialysis Transplantation, 2016, 32, gfw345.	0.4	15
204	Hemodialysis patients with intradialytic rise in blood pressure display higher baseline aortic stiffness and negligible drop in augmentation index with dialysis. International Urology and Nephrology, 2016, 48, 601-608.	0.6	11
205	New Potassium Binders: A Call to Test Their Efficacy and Safety in Dialysis Patients. American Journal of Kidney Diseases, 2016, 67, 165-166.	2.1	4
206	To intervene or not? A man with multidrug-resistant hypertension, endovascular abdominal aneurysm repair, bilateral renal artery stenosis and end-stage renal disease salvaged with renal artery stenting. Blood Pressure, 2016, 25, 123-128.	0.7	7
207	Diabetes mellitus increases the prevalence of anemia in patients with chronic kidney disease: A nested case-control study. World Journal of Nephrology, 2016, 5, 358.	0.8	47
208	Resistant Hypertension in Chronic Kidney Disease. , 2016, , 85-105.		0
209	Intervention Associated Acute Kidney Injury and Long-Term Cardiovascular Outcomes. American Journal of Nephrology, 2015, 42, 285-294.	1.4	33
210	Sodium–glucose cotransporter-2 inhibitors and blood pressure decrease. Journal of Hypertension, 2015, 33, 2185-2197.	0.3	60
211	New insights into cardiovascular risk factors and outcomes. Nature Reviews Nephrology, 2015, 11, 70-72.	4.1	13
212	Impact of Chronic Kidney Disease and Diabetes Mellitus on Choice of Renin Angiotensin System-Inhibitors in Patients with Hypertension and Heart Failure. , 2015, , 73-118.		0
213	Renal dysfunction after endovascular abdominal aortic aneurysm repair: time to use the correct outcome measures. Kidney International, 2015, 88, 1199.	2.6	8
214	Prevalence of Hyperkalemia in Diabetic and Non-Diabetic Patients with Chronic Kidney Disease: A Nested Case-Control Study. American Journal of Nephrology, 2015, 42, 351-360.	1.4	35
215	Pro: Should we move to more frequent haemodialysis schedules?. Nephrology Dialysis Transplantation, 2015, 30, 18-22.	0.4	18
216	Opponent's comment. Nephrology Dialysis Transplantation, 2015, 30, 27-28.	0.4	0

#	Article	IF	CITATIONS
217	Patient Cases: 1. A Patient with Apparent Compliance. High Blood Pressure and Cardiovascular Prevention, 2015, 22, 15-18.	1.0	3
218	Adverse Effects of Conventional Thrice-Weekly Hemodialysis: Is It Time to Avoid 3-Day Interdialytic Intervals?. American Journal of Nephrology, 2015, 41, 400-408.	1.4	41
219	Intradialysis Hypertension in End-Stage Renal Disease Patients. Hypertension, 2015, 66, 456-463.	1.3	45
220	Ambulatory Recording of Wave Reflections and Arterial Stiffness during Intra- and Interdialytic Periods in Patients Treated with Dialysis. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 630-638.	2.2	67
221	Economic evaluation of a single-pill triple antihypertensive therapy with valsartan, amlodipine, and hydrochlorothiazide against its dual components. Cost Effectiveness and Resource Allocation, 2015, 13, 10.	0.6	13
222	Long-Term Renal Function after Endovascular Aneurysm Repair. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 1930-1936.	2.2	42
223	Ambulatory aortic blood pressure, wave reflections and pulse wave velocity are elevated during the third in comparison to the second interdialytic day of the long interval in chronic haemodialysis patients. Nephrology Dialysis Transplantation, 2015, 30, 2046-2053.	0.4	35
224	Arterial Stiffness: A Novel Risk Factor for Kidney Injury Progression?. American Journal of Hypertension, 2015, 28, 958-965.	1.0	53
225	Ambulatory Blood Pressure Monitoring in the Diagnosis, Prognosis, and Management of Resistant Hypertension: Still a Matter of our Resistance?. Current Hypertension Reports, 2015, 17, 78.	1.5	18
226	Advances in treatment of hyperkalemia in chronic kidney disease. Expert Opinion on Pharmacotherapy, 2015, 16, 2205-2215.	0.9	31
227	Arterial Stiffness: A Novel Cardiovascular Risk Factor in Kidney Disease Patients. Current Vascular Pharmacology, 2015, 13, 229-238.	0.8	64
228	The Authors Reply:. Kidney International, 2014, 86, 855.	2.6	0
229	Aggressive blood pressure reduction and renin–angiotensin system blockade in chronic kidney disease: time for re-evaluation?. Kidney International, 2014, 85, 536-546.	2.6	64
230	Reninâ€Angiotensin System Blockade and Exerciseâ€Induced Increase in Aortic Stiffness. Journal of Clinical Hypertension, 2014, 16, 475-476.	1.0	0
231	Comparative Epidemiology of Resistant Hypertension in Chronic Kidney Disease and the General Hypertensive Population. Seminars in Nephrology, 2014, 34, 483-491.	0.6	26
232	Early Patterns of Blood Pressure Change and Future Coronary Atherosclerosis. JAMA - Journal of the American Medical Association, 2014, 311, 471.	3.8	7
233	Evaluation of a Novel Brachial Cuff-Based Oscillometric Method for Estimating Central Systolic Pressure in Hemodialysis Patients. American Journal of Nephrology, 2014, 40, 242-250.	1.4	60
234	Hemodiafiltration Does Not Have Additional Benefits over Hemodialysis on Arterial Stiffness, Wave Reflections and Central Aortic Pressures. Blood Purification, 2014, 37, 18-26.	0.9	9

#	Article	IF	CITATIONS
235	Review of blood pressure control rates and outcomes. Journal of the American Society of Hypertension, 2014, 8, 127-141.	2.3	55
236	Renin inhibition in patients with chronic kidney disease: Is it conclusively non-indicated?. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2014, 15, 97-98.	1.0	3
237	Comparison of the impact of open and endovascular abdominal aortic aneurysm repair onÂrenal function. Journal of Vascular Surgery, 2014, 60, 597-603.	0.6	39
238	Impaired renal function is associated with mortality and morbidity after endovascular abdominal aortic aneurysm repair. Journal of Vascular Surgery, 2013, 58, 879-885.	0.6	45
239	Resistant hypertension—its identification and epidemiology. Nature Reviews Nephrology, 2013, 9, 51-58.	4.1	162
240	Differences Between Office and 24-Hour Blood Pressure Control in Hypertensive Patients With CKD: A 5,693-Patient Cross-sectional Analysis From Spain. American Journal of Kidney Diseases, 2013, 62, 285-294.	2.1	88
241	Elevated Asymmetric Dimethylarginine is Associated With Oxidant Stress Aggravation in Patients With Early Stage Autosomal Dominant Polycystic Kidney Disease. Kidney and Blood Pressure Research, 2013, 38, 72-82.	0.9	29
242	Diverse effects of interdialytic intervals on central wave augmentation in haemodialysis patients. Nephrology Dialysis Transplantation, 2013, 28, 2160-2169.	0.4	28
243	Effects of Low-Dose Atorvastatin on Arterial Stiffness and Central Aortic Pressure Augmentation in Patients With Hypertension and Hypercholesterolemia. American Journal of Hypertension, 2013, 26, 608-616.	1.0	90
244	A Novel Technique for Repositioning, under Local Anesthetic, Malfunctioning and Migrated Peritoneal Dialysis Catheters. Peritoneal Dialysis International, 2013, 33, 700-704.	1.1	5
245	Obesity Does Not Influence Hepcidin and Hemojuvelin Levels in Hemodialysis Patients. Nephron Clinical Practice, 2013, 124, 159-166.	2.3	0
246	Cardiorenal disease development under chronic renin–angiotensin–aldosterone system suppression. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2012, 13, 217-219.	1.0	19
247	Prevalence and Factors Associated with Hyperkalemia in Predialysis Patients Followed in a Low-Clearance Clinic. Clinical Journal of the American Society of Nephrology: CJASN, 2012, 7, 1234-1241.	2.2	128
248	Use of a Single Target Blood Pressure Level in Type 2 Diabetes Mellitus for All Cardiovascular Risk Reduction. Archives of Internal Medicine, 2012, 172, 1304.	4.3	6
249	Obesity and iron deficiency in chronic kidney disease: the putative role of hepcidin. Nephrology Dialysis Transplantation, 2012, 27, 50-57.	0.4	13
250	Prevalence, Patterns of Treatment, and Control of Hypertension in Predialysis Patients with Chronic Kidney Disease. Nephron Clinical Practice, 2012, 120, c147-c155.	2.3	38
251	Compliance With a Structured Weight Loss Program Is Associated With Reduced Systolic Blood Pressure in Obese Patients With Chronic Kidney Disease. American Journal of Hypertension, 2012, 25, 1024-1029.	1.0	25
252	Ambulatory Blood Pressure Monitoring: An Invaluable Tool Comes of Age for Patients with Chronic Kidney Disease. American Journal of Nephrology, 2012, 35, 238-241.	1.4	16

#	Article	IF	CITATIONS
253	A reappraisal of renin–angiotensin system blockade on microalbuminuria development. Journal of Hypertension, 2012, 30, 48-50.	0.3	2
254	Pharmacological management of hypertensive emergencies and urgencies: focus on newer agents. Expert Opinion on Investigational Drugs, 2012, 21, 1089-1106.	1.9	26
255	Total protein, albumin and low-molecular-weight protein excretion in HIV-positive patients. BMC Nephrology, 2012, 13, 85.	0.8	33
256	Intra-individual variability of serum hepcidin-25 in haemodialysis patients using mass spectrometry and ELISA. Nephrology Dialysis Transplantation, 2012, 27, 3923-3929.	0.4	20
257	Serum Hemojuvelin and Hepcidin Levels in Chronic Kidney Disease. American Journal of Nephrology, 2012, 35, 295-304.	1.4	24
258	Suprarenal graft fixation in endovascular abdominal aortic aneurysm repair is associated with a decrease in renal function. Journal of Vascular Surgery, 2012, 56, 594-600.	0.6	40
259	Hypertension and Symptomatic Hypokalemia in a Patient With Simultaneous Unilateral Stenoses of Intrarenal Arteries and Mesangioproliferative Glomerulonephritis. American Journal of Kidney Diseases, 2012, 59, 434-438.	2.1	3
260	A study of the association of higher parathormone levels with health-related quality of life in hemodialysis patients. Clinical Nephrology, 2012, 77, 196-203.	0.4	17
261	PPAR-Î ³ Agonism for Cardiovascular and Renal Protection. Cardiovascular Therapeutics, 2011, 29, 377-384.	1.1	17
262	Epidemiology of Resistant Hypertension. Journal of Clinical Hypertension, 2011, 13, 523-528.	1.0	53
263	Microscopic Hematuria in Adolescents and Young Adults and Risk for End-stage Renal Disease. JAMA - Journal of the American Medical Association, 2011, 306, 1980-1980.	3.8	1
264	Hemodialysis Reduces Augmentation Index but Not Aortic or Brachial Pulse Wave Velocity in Dialysis-Requiring Patients. American Journal of Nephrology, 2011, 34, 407-414.	1.4	41
265	Effect of Thiazolidinediones on Albuminuria and Proteinuria in Diabetes: A Meta-analysis. American Journal of Kidney Diseases, 2010, 55, 835-847.	2.1	175
266	Evaluation and Treatment of Hypertensive Urgencies and Emergencies. , 2010, , 445-450.		2
267	Effects of Renin-Angiotensin System Inhibition on Left Atrial Function of Hypertensive Patients: An Echocardiographic Tissue Deformation Imaging Study. American Journal of Hypertension, 2010, 23, 556-561.	1.0	27
268	Effect of hospitalization on 24-h ambulatory blood pressure of hypertensive patients. Hypertension Research, 2010, 33, 995-999.	1.5	6
269	Diuretics in clinical practice. Part I: mechanisms of action, pharmacological effects and clinical indications of diuretic compounds. Expert Opinion on Drug Safety, 2010, 9, 243-257.	1.0	45
270	Diuretics in clinical practice. Part II: electrolyte and acid-base disorders complicating diuretic therapy. Expert Opinion on Drug Safety, 2010, 9, 259-273.	1.0	38

#	Article	IF	CITATIONS
271	Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet, The, 2010, 375, 1173-1181.	6.3	472
272	Endothelin antagonism for diabetic nephropathy. Nature Reviews Nephrology, 2010, 6, 447-449.	4.1	13
273	Scleroderma Renal Crisis Accompanied by New-Onset Pulmonary Hypertension: An Acute Systemic Endothelial Injury? Case Report and Literature Review. Inflammation and Allergy: Drug Targets, 2010, 9, 313-318.	1.8	6
274	Oral Calcium Supplementation Ambulatory Blood Pressure and Relation to Changes in Intracellular Ions and Sodium-Hydrogen Exchange. American Journal of Hypertension, 2009, 22, 1263-1269.	1.0	6
275	The controversial effects of thiazolidinediones on cardiovascular morbidity and mortality. International Journal of Cardiology, 2009, 131, 298-304.	0.8	54
276	Oral Magnesium Supplementation Reduces Ambulatory Blood Pressure in Patients With Mild Hypertension. American Journal of Hypertension, 2009, 22, 1070-1075.	1.0	67
277	Familial burden of hypertension and its effect on blood pressure levels, insulin resistance, and intracellular ions in Greek offspring. Journal of the American Society of Hypertension, 2009, 3, 141-149.	2.3	1
278	Effects of Thiazolidinediones Beyond Glycaemic Control. Current Pharmaceutical Design, 2009, 15, 529-536.	0.9	46
279	Does Evidence Support Renin–Angiotensin System Blockade for Slowing Nephropathy Progression in Elderly Persons?. Annals of Internal Medicine, 2009, 150, 731.	2.0	20
280	Insulin resistance, microalbuminuria, and chronic kidney disease. Current Hypertension Reports, 2008, 10, 249-251.	1.5	7
281	Thiazolidinedione derivatives in diabetes and cardiovascular disease: an update. Fundamental and Clinical Pharmacology, 2008, 22, 247-264.	1.0	36
282	Insulin Resistance and Endothelin: Another Pathway for Renal Injury in Patients With the Cardiometabolic Syndrome?. Journal of the Cardiometabolic Syndrome, 2008, 3, 183-187.	1.7	26
283	Reversal of Diuretic-Associated Impaired Glucose Tolerance and New-Onset Diabetes: Results of the STAR-LET Study. Journal of the Cardiometabolic Syndrome, 2008, 3, 18-25.	1.7	20
284	State of Hypertension Management in the United States: Confluence of Risk Factors and the Prevalence of Resistant Hypertension. Journal of Clinical Hypertension, 2008, 10, 130-139.	1.0	97
285	Comparative Efficacy of Two Different β-Blockers on 24-Hour Blood Pressure Control. Journal of Clinical Hypertension, 2008, 10, 112-118.	1.0	13
286	A Comparative Evaluation of Various Methods for Microalbuminuria Screening. American Journal of Nephrology, 2008, 28, 324-329.	1.4	36
287	Resistant Hypertension. Journal of the American College of Cardiology, 2008, 52, 1749-1757.	1.2	304
288	Increase in Oxidative Stress but Not in Antioxidant Capacity with Advancing Stages of Chronic Kidney Disease. American Journal of Nephrology, 2008, 28, 397-404.	1.4	95

#	Article	IF	CITATIONS
289	Hypertension Awareness, Treatment, and Control in Chronic Kidney Disease. American Journal of Medicine, 2008, 121, 332-340.	0.6	250
290	Renin-angiotensin blockade and kidney disease. Lancet, The, 2008, 372, 511-512.	6.3	51
291	Effects of Renin-Angiotensin System Blockers on Renal Outcomes and All-cause Mortality in Patients With Diabetic Nephropathy: An Updated Meta-analysis. American Journal of Hypertension, 2008, 21, 922-929.	1.0	80
292	Sustained Hypotension Complicating an Extra-adrenal Pheochromocytoma. American Journal of Hypertension, 2008, 21, 840-842.	1.0	7
293	Obesity, insulin resistance and kidney disease risk: insights into the relationship. Current Opinion in Nephrology and Hypertension, 2008, 17, 450-456.	1.0	50
294	Carvedilol in hypertension treatment. Vascular Health and Risk Management, 2008, 4, 23-30.	1.0	72
295	Validity and reproducibility of HOMA-IR, 1/HOMA-IR, QUICKI and McAuley's indices in patients with hypertension and type II diabetes. Journal of Human Hypertension, 2007, 21, 709-716.	1.0	150
296	The Antinatriuretic Effect of Insulin: An Unappreciated Mechanism for Hypertension Associated with Insulin Resistance?. American Journal of Nephrology, 2007, 27, 44-54.	1.4	70
297	Slow Intravenous Iron Administration Does Not Aggravate Oxidative Stress and Inflammatory Biomarkers during Hemodialysis: A Comparative Study between Iron Sucrose and Iron Dextran. American Journal of Nephrology, 2007, 27, 572-579.	1.4	34
298	Insulin and Endothelin: An Interplay Contributing to Hypertension Development?. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 379-385.	1.8	92
299	Effects of Statins on Blood Pressure: A Review of the Experimental and Clinical Evidence Current Vascular Pharmacology, 2007, 5, 155-161.	0.8	10
300	Metabolic syndrome and arterial stiffness: evidence for gender disparity and early effects of non-traditional risk factors?. Journal of Hypertension, 2007, 25, 935-938.	0.3	12
301	Metabolic effects of Î2-blockers: importance of dissociating newer from conventional agents. Journal of Hypertension, 2007, 25, 249-252.	0.3	14
302	Statins and Blood Pressure: Is There an Effect or Not?. Journal of Clinical Hypertension, 2007, 9, 460-467.	1.0	10
303	A Costâ€Effectiveness Analysis of Angiotensinâ€Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Diabetic Nephropathy. Journal of Clinical Hypertension, 2007, 9, 751-759.	1.0	8
304	Blood Pressure and Serum Potassium Levels in Hypertensive Patients Receiving or Not Receiving Antihypertensive Treatment. Clinical and Experimental Hypertension, 2007, 29, 563-573.	0.5	17
305	Non-esterified fatty acids and blood pressure elevation: a mechanism for hypertension in subjects with obesity/insulin resistance?. Journal of Human Hypertension, 2007, 21, 12-19.	1.0	81
306	Are antihypertensive drugs associated with an increased risk of incident type 2 diabetes?. Nature Clinical Practice Endocrinology and Metabolism, 2007, 3, 8-9.	2.9	1

#	Article	IF	CITATIONS
307	Insulin Resistance and Oxidant Stress: An Interrelation With Deleterious Renal Consequences?. Journal of the Cardiometabolic Syndrome, 2007, 2, 139-142.	1.7	15
308	Rosiglitazone and Cardiovascular Risk: Weighing Recent Evidence. Journal of the Cardiometabolic Syndrome, 2007, 2, 295-296.	1.7	5
309	Thiazolidinediones and Diabetic Nephropathy: Need for a Closer Examination?. Journal of the Cardiometabolic Syndrome, 2007, 2, 297-301.	1.7	5
310	Antihypertensive Therapy in the Presence of Proteinuria. American Journal of Kidney Diseases, 2007, 49, 12-26.	2.1	671
311	Antihypertensive agents, insulin sensitivity, and new-onset diabetes. Current Diabetes Reports, 2007, 7, 191-199.	1.7	42
312	Insulin Resistance, Hyperinsulinemia, and Hypertension: An Epidemiologic Approach. Journal of the Cardiometabolic Syndrome, 2006, 1, 334-344.	1.7	16
313	Microalbuminuria. Clinics in Laboratory Medicine, 2006, 26, 635-653.	0.7	56
314	Insulin Resistance, Hyperinsulinemia, and Renal Injury: Mechanisms and Implications. American Journal of Nephrology, 2006, 26, 232-244.	1.4	227
315	Actions of Peroxisome Proliferator–Activated Receptors–γ Agonists Explaining a Possible Blood Pressure–Lowering Effect. American Journal of Hypertension, 2006, 19, 646-653.	1.0	72
316	The metabolic syndrome: a glance at its history. Journal of Hypertension, 2006, 24, 621-626.	0.3	138
317	Gender disparity in outcomes of care and management for diabetes and the metabolic syndrome. Current Diabetes Reports, 2006, 6, 219-224.	1.7	42
318	Microalbuminuria and chronic kidney disease as risk factors for cardiovascular disease. Nephrology Dialysis Transplantation, 2006, 21, 2366-2374.	0.4	100
319	Antihypertensive treatment with beta-blockers and the spectrum of glycaemic control. QJM - Monthly Journal of the Association of Physicians, 2006, 99, 431-436.	0.2	66
320	The effects of thiazolidinediones on blood pressure levels – A systematic review. Blood Pressure, 2006, 15, 135-150.	0.7	62
321	Differences in Glucose Tolerance Between Fixed-Dose Antihypertensive Drug Combinations in People With Metabolic Syndrome. Diabetes Care, 2006, 29, 2592-2597.	4.3	175
322	The effect of rosiglitazone on novel atherosclerotic risk factors in patients with type 2 diabetes mellitus and hypertension. Metabolism: Clinical and Experimental, 2005, 54, 1236-1242.	1.5	45
323	The effect of rosiglitazone on urine albumin excretion in patients with type 2 diabetes mellitus and hypertension. American Journal of Hypertension, 2005, 18, 227-234.	1.0	45
324	What lies behind the intense criticism of ALLHAT?. Journal of Hypertension, 2004, 22, 223-224.	0.3	5

#	Article	IF	CITATIONS
325	Ambulatory blood pressure reduction after rosiglitazone treatment in patients with type 2 diabetes and hypertension correlates with insulin sensitivity increase. Journal of Hypertension, 2004, 22, 1769-1777.	0.3	70
326	Renal artery stenting in the correct patients with atherosclerotic renovascular disease: time for a proper renal and cardiovascular outcome study?. CKJ: Clinical Kidney Journal, 0, , .	1.4	2
327	Peripheral endothelial and microvascular damage in liver cirrhosis: a systematic review and metaâ€analysis. Microcirculation, 0, , .	1.0	0
328	Ambulatory blood pressure trajectories and blood pressure variability in kidney transplant recipients: a comparative study against chronic kidney disease patients. Kidney Research and Clinical Practice, 0, , .	0.9	5
329	A parallel evaluation of short and mid-term changes of ambulatory BP in kidney transplant recipients and kidney donors. CKJ: Clinical Kidney Journal, 0, , .	1.4	3